Atsushi Kosaka Naoya Sakamoto Mayu Hikone Kazuo Imai Masayuki Ota Takuya Washino Takuya Maeda Sentarou Iwabuchi
10.2169/internalmedicine.4096-19
Intern Med
2020;59(9):1227-1230.
leishmania braziliensis cutaneous leishmaniasis liposomal-amphotericin b
CC BY-NC-ND
https://pubmed.ncbi.nlm.nih.gov/32378656/
Amphotericin B / therapeutic use Antiprotozoal Agents / therapeutic use Leishmania braziliensis / isolation & purification Leishmaniasis, Cutaneous / diagnosis
Amphotericin B / therapeutic use Antiprotozoal Agents / therapeutic use Leishmania braziliensis / isolation & purification Leishmaniasis, Cutaneous / diagnosis Case Reports Amphotericin B / administration & dosage Antiprotozoal Agents / administration & dosage Diagnosis, Differential Dose-Response Relationship, Drug Humans Leishmaniasis, Cutaneous / complications Leishmaniasis, Cutaneous / drug therapy Male Middle Aged Retreatment Treatment Failure Antiprotozoal Agents liposomal amphotericin B Amphotericin B
PMC7270753
32378656
Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis due to Leishmania braziliensis
2020